跳至主要内容
临床试验/NCT00772564
NCT00772564已完成4 期

The Use of Statins for Myocardial Death Prevention: From Cell to Bedside

Rambam Health Care Campus1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2008年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
25
试验地点
1
主要终点
Heart EcoCardiography and specific laboratory tests

研究概览

简要总结

The administration of high dose HMG-CoA reductase inhibitors (Statins) to patients with acute ST-elevation MI (hypoxia/ischemia) who are treated with primary PCI (reoxygenation/ reperfusion) will protect their cardiomyocytes from death and thus preserve LV ejection fraction.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
30 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients suffering from acute ST elevation resulting from myocardial infarction, Killip Classification 1 and 2 will be included at-random to either group. Included subjects should be able to give their informed consent to participate in this study.

排除标准

  • The impossibility to give the required informed consent.
  • Known allergy to Atorvastatin.
  • Base line serum creatinine of 1.4 mg/dL.
  • Killip Classification 3 and
  • Persisting vomiting.
  • History of previous liver disease.
  • History of previous muscle disease or rabdomyolisis.
  • Treated already with high dose atorvastatin
  • Non Compliance.

研究组 & 干预措施

Atorvastatin 80 mg

Experimental

干预措施: Atorvastatin (Drug)

Atorvastatin 10 mg

Experimental

干预措施: Atorvastatin (Drug)

结局指标

主要结局

Heart EcoCardiography and specific laboratory tests

时间窗: Base line, second day and 60 days after myocardial infarction

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

N_Krivoy

Clinical Pharmacology Unit

Rambam Health Care Campus

研究点 (1)

Loading locations...

相似试验